Company: ILLRW
Filing Date: 2025-01-24
Form Type: S-1
Source: 0001213900-25-006210
Chunk: 335

Company: Triller Group Inc.
Filing Date: 2025-01-24
Form: S-1
Chunk 335
---
 |             — |     |     |      4.00 | %  |     |   |    2,152,251 |
|                                    |     |       |           |    |     |   |    24,469,558 |     |     |           |    |     |   |   25,723,869 |
| Investment G under purchase option |     |       |           |    |     |   |     6,028,100 |     |     |           |    |     |   |            — |
| Net carrying value                 |     |       |           |    |     | $ |    30,499,038 |     |     |           |    |     | $ |   25,724,464 |

| * | Less        
 than 0.001% |

Investments in Marketable Equity Securities

Investments in equity securities, such as, marketable
securities, are accounted for at its current market value with the changes in fair value recognized in net gain (loss). Investment C was
listed and publicly traded on Nasdaq Stock Exchange.

As of September 30, 2024 and December 31, 2023,
Investment C was recorded at fair value of $ and $, which were traded at a closing price of $ and $ per share, respectively.

Investments in Non-Marketable Equity Securities

Investments in non-marketable equity securities
consist of investments in limited liability companies in which the Company’s interests are deemed minor and long-term, strategic
investments in companies that are in various stages of development, and investments in close-ended partnership funds which concentrated
in the healthcare sector. These investments do not have readily determinable fair values and, therefore, are reported at cost, minus impairment,
if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment
of the same issuer.

<div align='center'>F-25

TRILLER GROUP INC.

(Formerly AGBA Group Holding Limited)

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 AND 2023

(Currency expressed in United States Dollars (“US$”),
except for number of shares)</div>

Management assesses each of these investments
on an individual basis, subject to a periodic impairment review and considers qualitative and quantitative factors including the investee’s